— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. 14, 2024 – Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan … Read more
FITCI Grad builds upon an unprecedented three Breakthrough Medical Device designations by the FDA Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded … Read more
KnowledgeNet.ai and LeadLander are thrilled to announce that they have teamed up to make a powerful collaborative solution available for customers in the fields of prospect research and business development. KnowledgeNet.ai, the AI-relationship intelligence tool for business that connects siloed interactions and information, is excited to combine its organization-wide view of past and present contacts … Read more
The life sciences media and events company and Frederick entrepreneurial incubator and accelerator will work together to fuel growth in the life sciences industry and BioHealth Capital Region. MARYLAND, March 23, 2023 — BioBuzz, the media outlet of Workforce Genetics, and the Frederick Innovative Technology Center, Inc. (FITCI) have announced a strategic partnership to fuel … Read more
© Copyright 2018 - 2026 FITCI. All Rights Reserved.
The Frederick Innovative Technology Center, Inc. (FITCI) is a 501(c)(3) nonprofit business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland.
Website Built by Wellspring Digital
